Analysis-AstraZenecas US listing may pull other firms from London in its wake
LONDON (Reuters) -AstraZeneca’s move to upgrade its listing in the U.S. risks pulling liquidity away from London’s stock market and…
78,250€
0,97%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
AstraZeneca Aktie NYSE Listing 2025: Große Wende oder cleverer Schachzug?
Bad Marienberg (www.aktiencheck.de) - AstraZeneca schaltet direktes Listing in New York – bleibt aber im UKAstraZeneca vollzieht strategischen Börseschachzug …
AstraZenecas New York listing tweak dubbed a knock-back for London
Shares in AstraZeneca PLC (LSE:AZN) rose on Monday as it shared plans to directly list its shares on the New York Stock…
AstraZeneca plans New York Stock Exchange listing but isn’t quitting London
FTSE 100’s second-biggest firm will also retain HQ in Cambridge and maintain its London listing…
AstraZeneca to list directly on NYSE while keeping U.K. listing; shares up By Investing.com
AstraZeneca to list directly on NYSE while keeping U.K. listing; shares up…
FTSE 100 Live: London stocks near all-time high as GSK and AstraZeneca rise
FTSE 100 up 62 points to 9,346 GSK rises as CEO change announced Gold miners lifted as precious metal prices…
AstraZeneca switches to direct US listing, keeps UK listing By Reuters
AstraZeneca switches to direct US listing, keeps UK listing…
AstraZeneca Boosts US Listing In Latest Pivot Away From UK
AstraZeneca Plc, the UK’s biggest drugmaker, plans to list regular shares on the New York Stock Exchange to attract more…
AstraZeneca to cut some direct-to-patient US drug prices after Trump demand
AstraZeneca said on Friday it will sell its diabetes and asthma drugs direct to cash-paying U.S. patients at a discount…
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
The latest trading day saw Astrazeneca (AZN) settling at $73.53, representing a -2.43% change from its previous close.…
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite…
AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire
AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with…
FTSE 100 gives up early gains as Kingfisher surges
The FTSE 100 gave up early gains on Tuesday as losses in heavyweights such as BAE Systems and AstraZeneca offset…
Astrazeneca (AZN) Stock Slides as Market Rises: Facts to Know Before You Trade
Astrazeneca (AZN) closed at $76.28 in the latest trading session, marking a -1.03% move from the prior day.…
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.…
Puma (PBYI) Q2 Revenue Rises 11%
Key PointsNon-GAAP EPS was $0.15, beating the non-GAAP estimate of $0.09 and turning positive on a GAAP basis from a…
Arcutis (ARQT) Q2 Revenue Soars 164%
Key PointsRevenue (GAAP) soared 164% year over year to $81.5 million, surpassing analyst estimates by $7.81 million (GAAP).Net loss per…
Proactive weekly health highlights: AstraZeneca, GSK, hVIVO, Avacta, and more
…
Total Voting Rights
1 August 2025
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…
Kimberly-Clark, Hims & Hers Health, CNH Industrial
U.S. stock index futures extended losses on Friday after a weaker-than-expected July jobs report elevated concerns about the health of…